You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.
In Nature this week: large Alzheimer's disease GWAS uncovers novel loci, new CRISPR interference-based approach, and more.
The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.
The Vanderbilt Center for Undiagnosed Diseases will use FDNA's Face2Gene to help evaluate difficult-to-diagnose patients.
PreventionGenetics will use FDNA's technology to expand the diagnostic ability of its testing and interpretation services.
FDNA's technology uses facial analysis, deep learning, and AI to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses.
The partnership combines sequencing with phenotype information to help diagnose patients with rare diseases.
MCRI is planning to integrate its POSSUMweb database into FDNA's Face2Gene software, in order to enhance its library of genetic syndrome data and images.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.
In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.
A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.
In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.